摘要
目的探讨洛伐他汀联合脂必妥治疗高脂血症的临床价值。方法将我中心2012年1月～2013年5月收治的高脂血症患者168例按不同治疗方法分为实验组（洛伐他汀＋脂必妥）和对照组（洛伐他汀），均治疗8周后对两组患者的治疗效果进行综合比较。结果实验组总有效率为90．47％，明显优于对照组的75．00％（P〈0．05），实验组的总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL—C）、TC—HDL—C／HDL—C均较对照组明显降低（P〈0．05），高密度脂蛋白胆固醇（HDL—C）较对照组明显升高（P〈0．05）。结论洛伐他汀联合脂必妥治疗高脂血症的临床效果显著，且有较高安全性，值得临床推广应用。
Objective To investigate the Clinical application value of lovastatin combined with Zhibituo in patients with hyperlipidemia. Methods 168 cases patients with hyperlipidemia in our hospital from January 2012 to May 2013 were divided into control group （lovastatin） and experimental group （lovastatin＋zhibituo）, the efficacy of two groups were compared after 8 weeks. Results The total effective-rate of experimental group was 90.47%,which was higher than that of control group（75.00%）（P 〈 0.05） and the experimental group showed significantly lower level of total cholesterine, glycerine, low density lipoprotein cholesterol, TC-HDL-C/HDL-C and higher high density lipoprotein cholesterol than the control group（P 〈 0.05）. Conclusion Lovastatin combined with Zhibituo has a significant effects on treating hyperlipidemia, which is worthy of clinical widely.
出处
《中国医药科学》
2013年第20期59-60,共2页
China Medicine And Pharmacy
